CoChat
Sign Up
Cited by 398

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

A targeted mutational landscape of angioimmunoblastic T-cell lymphoma

Odejide, Oreofe, Weigert, Oliver, Lane, Andrew A., Toscano, Dan, Lunning, Matthew A., Kopp, Nadja, Kim, Sunhee, van Bodegom, Diederik, Bolla, Sudha, Schatz, Jonathan H., Teruya-Feldstein, Julie, Hochberg, Ephraim, Louissaint, Abner, Dorfman, David, Stevenson, Kristen, Rodig, Scott J., Piccaluga, Pier Paolo, Jacobsen, Eric, Pileri, Stefano A., Harris, Nancy L., Ferrero, Simone, Inghirami, Giorgio, Horwitz, Steven M., Weinstock, David M.·2014·Blood
DOI 10.1182/blood-2013-10-531509
Open this paper in CoChat — free account

Abstract

Key Points: AITL is characterized by high frequencies of overlapping mutations in epigenetic modifiers, including TET2, IDH2, and DNMT3A. Targetable mutations are present in a subset of cases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2013-10-531509

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 22

  1. Siegert, 1995, Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation., Ann Oncol, 6, 659, 10.1093/oxfordjournals.annonc.a059281 · DOI
  2. Federico, Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the International Peripheral T-Cell Lymphoma Project., J Clin Oncol
  3. Vose, 2008, International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes., J Clin Oncol, 26, 4124, 10.1200/JCO.2008.16.4558 · DOI
  4. Pautier, 1999, Angioimmunoblastic-like T-cell non Hodgkin’s lymphoma: outcome after chemotherapy in 33 patients and review of the literature., Leuk Lymphoma, 32, 545, 10.3109/10428199909058412 · DOI
  5. Piccaluga, 2013, Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study., J Clin Oncol, 31, 3019, 10.1200/JCO.2012.42.5611 · DOI
  6. Cairns, 2012, IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma., Blood, 119, 1901, 10.1182/blood-2011-11-391748 · DOI
  7. Lemonnier, 2012, Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters., Blood, 120, 1466, 10.1182/blood-2012-02-408542 · DOI · Paper page
  8. Couronné, 2012, TET2 and DNMT3A mutations in human T-cell lymphoma., N Engl J Med, 366, 95, 10.1056/NEJMc1111708 · DOI · Paper page
  9. Cheung, 2010, Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis., Cancer Res, 70, 9166, 10.1158/0008-5472.CAN-10-2460 · DOI
  10. Morin, 2010, Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin., Nat Genet, 42, 181, 10.1038/ng.518 · DOI · Paper page
  11. Kridel, 2012, Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma., Blood, 119, 1963, 10.1182/blood-2011-11-391474 · DOI
  12. Steidl, 2011, MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers., Nature, 471, 377, 10.1038/nature09754 · DOI
  13. Pasqualucci, 2011, Inactivating mutations of acetyltransferase genes in B-cell lymphoma., Nature, 471, 189, 10.1038/nature09730 · DOI
  14. Lenz, 2008, Oncogenic CARD11 mutations in human diffuse large B cell lymphoma., Science, 319, 1676, 10.1126/science.1153629 · DOI
  15. Balatti, 2012, NOTCH1 mutations in CLL associated with trisomy 12., Blood, 119, 329, 10.1182/blood-2011-10-386144 · DOI
  16. Puente, 2011, Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia., Nature, 475, 101, 10.1038/nature10113 · DOI
  17. Wagle, 2012, High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing., Cancer Discov, 2, 82, 10.1158/2159-8290.CD-11-0184 · DOI
  18. Lane, 2013, Low frequency clonal mutations recoverable by deep sequencing in patients with aplastic anemia., Leukemia, 27, 968, 10.1038/leu.2013.30 · DOI
  19. Jatiani, 2010, Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies., Genes Cancer, 1, 979, 10.1177/1947601910397187 · DOI
  20. Jerez, 2012, STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia., Blood, 120, 3048, 10.1182/blood-2012-06-435297 · DOI
  21. Koskela, 2012, Somatic STAT3 mutations in large granular lymphocytic leukemia., N Engl J Med, 366, 1905, 10.1056/NEJMoa1114885 · DOI
  22. Quivoron, 2011, TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis., Cancer Cell, 20, 25, 10.1016/j.ccr.2011.06.003 · DOI · Paper page

Cited by

See all 398

Metadata

Authors
Odejide, O., Weigert, O., Lane, A. A., Toscano, D., Lunning, M. A., Kopp, N., Kim, S., van Bodegom, D., Bolla, S., Schatz, J. H., Teruya-Feldstein, J., Hochberg, E., Louissaint, A., Dorfman, D., Stevenson, K., Rodig, S. J., Piccaluga, P. P., Jacobsen, E., Pileri, S. A., Harris, N. L., Ferrero, S., Inghirami, G., Horwitz, S. M., & Weinstock, D. M.
Affiliations
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;
  • Department of Medicine and
  • Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY;
  • Department of Pathology, Massachusetts General Hospital, Boston, MA;
  • Department of Pathology, Brigham and Women’s Hospital, Boston, MA;
  • Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA;
  • Unit of Hematopathology, Orsola Malpighi Hospital, Bologna, Italy; and
  • Divisione di Ematologia, Universita di Torino, Torino, Italy
Venue
Blood
Publisher
American Society of Hematology
Published
2014-02-27
Volume
123
Issue
9
Pages
1293-1296
ISSN
  • 0006-4971
  • 1528-0020
DOI
10.1182/blood-2013-10-531509
Cited by
398
References
2
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review